SERANasdaqServices-Medical LaboratoriesFiscal year ends December 31
SERA PROGNOSTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$2.03−0.03 (-1.46%)
Close on Oct 19, 2026
- Market cap
- $102.47M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.17 (−36.56%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
SERA PROGNOSTICS, INC. saw revenue fall 35.2% to $70.00K over the twelve months to Jun 30, 2026. Free cash flow was -$28.15M.
Revenue
$70.00K
-35.2% vs. a year earlier
Operating income
-$37.30M
TTM Q2 2026
Free cash flow
-$28.15M
TTM Q2 2026
EPS, diluted
-$0.67
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $102.47M
- P/E ratio
- –
- Price to sales
- 1463.83
- Price to book
- 1.73
- Dividend yield
- –
- Free cash flow yield
- -27.47%
Fundamentals
- Revenue
- $70.00K
- Net income
- -$33.23M
- EPS, diluted
- -$0.67
- Free cash flow
- -$28.15M
- Book value per share
- $1.18
- Diluted shares
- 50M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$70.00K-35.2% YoY
Gross profit
-$105.00K
Operating income
-$37.30M
Net income
-$33.23M
EPS, diluted
-$0.67
Free cash flow
-$28.15M
Reported periodTrailing twelve months